Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[THE OVERLAPPING ELIGIBILITY FOR BIOLOGICS IN PATIENTS WITH SEVERE ASTHMA AND PHENOTYPES].

Arerugi = [Allergy] - 1 Jan 2022

Ito Ayaka, Miyoshi Shoki, Toyota Hikaru, Suzuki Yuki, Uehara Yuki, Hattori Saya, Takeshita Yuri, Sakasegawa Hirokazu, Kuramochi Michio, Kobayashi Konomi, Sugimoto Naoya, Nagase Hiroyuki

Abstract excerpt

BACKGROUND: Biologics are an important treatment option for patients with severe asthma. Four biologics are available in Japan, and an overlapping eligibility has been observed. The eligibility and availability of drugs depend on the local regulations of different countries. However, there is no precise information about the eligibility for biologics, including dupilumab, in Japan. The aim of the study was to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Asthmatic Agents
Share to Asthma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biological Products

Share to Eosinophils

Share to Immunoglobulin E

Share to Interleukin-5

Share to Phenotype

Source

Identifiers

PMID: 35569943
DOI: 10.15036/arerugi.71.210

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[THE OVERLAPPING ELIGIBILITY FOR BIOLOGICS IN PATIENTS WITH SEVERE ASTHMA AND PHENOTYPES].PMID 35569943Read ↗

Biologics in severe asthma: the overlap endotype - opportunities and challenges.Semantic proximity Read ↗

Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A Consensus Statement.Semantic proximity Read ↗

Controversies and opportunities in severe asthma.Semantic proximity Read ↗

Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted ApproachSemantic proximity Read ↗

Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease: A Narrative ReviewSemantic proximity Read ↗

Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient.Semantic proximity Read ↗

Severe asthma phenotypes in patients controlled with omalizumab: A real-world study.Semantic proximity Read ↗

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read ↗

Defining Type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysisSemantic proximity Read ↗

Biologic Therapy and Novel Molecular Targets of Severe Asthma.Semantic proximity Read ↗

Effectiveness of mepolizumab in a real-life cohort of patients with severe refractory eosinophilic asthma and multiple comorbiditiesSemantic proximity Read ↗

Phenotypic characteristics of exacerbations in severe asthmatics receiving biological agent treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.